Philogen SpA (PHIL)

Currency in EUR
21.60
-0.40(-1.82%)
Real-time Data·
PHIL Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
PHIL is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
21.6022.00
52 wk Range
16.5027.80
Key Statistics
Prev. Close
22
Open
21.8
Day's Range
21.6-22
52 wk Range
16.5-27.8
Volume
1.08K
Average Volume (3m)
24.52K
1-Year Change
5.26%
Book Value / Share
3.44
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PHIL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
28.00
Upside
+29.63%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Philogen SpA News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Philogen SpA Company Profile

Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases in Switzerland and the European Union. The company develops Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF, which is in Phase III trial for the intralesional treatment of locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF in Phase III trial to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine interleukin-2 (IL2), which is in Phase II trial for the treatment of non-small cell lung cancer. It is also developing Dekavil (F8IL10), an anti-inflammatory product in Phase II trial for the treatment of chronic inflammatory disorders; Dodekin, a human immunostimulatory product that comprises vascular targeting antibody fused to interleukin-12, which is in Phase I trial to treat advanced solid tumors; OncoFAP radio conjugates, a small molecule radiotracer with ultra high affinity for fibroblast activation protein in Phase I trial for diagnostic and therapeutic applications of metastatic solid tumors; OncoACP3, a small molecule radiotracer with ultra high-affinity for acid phosphatase 3 in Phase I trial for diagnostic and therapeutic applications for prostate cancer; OncoCAIX, a small molecule radiotracer in Phase 1 trial for the detection of Carbonic Anhydrase IX (CAIX) expressed in renal cell carcinoma and other hypoxic tumors; and OncoFAP-GlyPro-MMAE, a small molecule drug conjugate with ultra-high affinity for fibroblast activation protein in preclinical trial for the treatment of solid tumors. Philogen S.p.A. was founded in 1996 and is headquartered in Siena, Italy.

Employees
183
Market
Italy

Compare PHIL to Peers and Sector

Metrics to compare
PHIL
Peers
Sector
Relationship
P/E Ratio
19.6x−3.4x−0.5x
PEG Ratio
0.020.010.00
Price/Book
6.4x1.3x2.6x
Price / LTM Sales
11.4x23.7x3.3x
Upside (Analyst Target)
27.3%94.3%42.8%
Fair Value Upside
Unlock−2.5%6.5%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 28.00
(+29.63% Upside)

Earnings

Latest Release
Apr 07, 2025
EPS / Forecast
1.51 / --
Revenue / Forecast
76.14M / --
EPS Revisions
Last 90 days

PHIL Income Statement

People Also Watch

19.445
PST
+0.13%
48.000
LDOF
-0.37%
5.244
NEXII
0.00%
70.1000
PRY
0.00%
32.6900
GASI
+0.49%

FAQ

What Stock Exchange Does Philogen SpA Trade On?

Philogen SpA is listed and trades on the Milan Stock Exchange stock exchange.

What Is the Stock Symbol for Philogen SpA?

The stock symbol for Philogen SpA is "PHIL."

What Is the Philogen SpA Market Cap?

As of today, Philogen SpA market cap is 887.30M.

What Is Philogen SpA's Earnings Per Share (TTM)?

The Philogen SpA EPS (TTM) is 1.12.

From a Technical Analysis Perspective, Is PHIL a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Philogen SpA Stock Split?

Philogen SpA has split 0 times.

How Many Employees Does Philogen SpA Have?

Philogen SpA has 183 employees.

What is the current trading status of Philogen SpA (PHIL)?

As of 06 Aug 2025, Philogen SpA (PHIL) is trading at a price of 21.60, with a previous close of 22.00. The stock has fluctuated within a day range of 21.60 to 22.00, while its 52-week range spans from 16.50 to 27.80.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.